This invention is related to methods and compositions effective for reducing hair growth. More specifically, the present invention is directed to methods for changing the rate of hair growth, reducing the size of the hair follicle and the hair shaft, and reducing hair shaft pigmentation, by topical application of either botanical extracts containing serine protease inhibitory activity and in particular soybean extracts such as soymilk, or mixtures and formulations of the above, combined with other active ingredients such as isoflavones.
One main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed essentially for social and cosmetic purposes.
Many procedures are used to remove unwanted hair including shaving, electrolysis, plucking, laser and light therapies and injection of therapeutic antiandrogens. These conventional methods are not without their shortcomings. Shaving, for instance, may result in nicks and cuts in the skin's surface, may leave a perception of an increase in the rate of hair regrowth, and may also leave undesirable stubble. While electrolysis may keep an area free of unwanted hair for a prolonged period of time, the process is often expensive and painful and may further result in scarring. Not only may plucking cause pain and discomfort, but it often result in a poor removal of short hair. Several unwanted side effects, such as effects on muscularity, often accompany the use of antiandrogens. For these reasons, better methods for reducing hair growth are needed.
Pseudofolliculitis barbae is an inflammatory hair disorder, most commonly found on the beard area. Inflammatory follicular papules result when hair tips penetrate into the skin rather than passing through the follicular orifice. This process is extremely common in black men because their hairs are frequently curly, exiting the skin at an acute angle. Close shaves, particularly with a razor blade, predispose them to pseudofolliculitis barbae. The most effective treatment available is to allow the hairs to grow well beyond the skin surface. Such a treatment is often not desired.
Hirsutism is a relatively frequent condition affecting about 4% of women. Facial hirsutism often interferes with personal and work activities, and temporary hair removal is a major component in the management of hirsute patients. Shaving is the most frequently used temporary method for facial hair, as plucking, waxing and depilatories are more difficult to tolerate and care must be taken to avoid folliculitis, pigmentation, and scarring. Cosmetic cover-ups are usually used to hide cuts and stubble and electrolysis and thermolysis may be used for permanent hair removal when affordable.
An alternative or complementary desired approach to hair removal, would be a method to reduce hair growth, reduce hair follicle and hair shaft size and reduce hair shaft pigmentation. Such an approach could reduce the visibility of existing hair, making it softer and lighter. When combined with other methods of hair removal such a method could enhance and prolong the removal effect, and reduce the need and frequency of hair removal. Long term use of such an approach could lead to attenuated, soft, pigmentation-reduced hair growth, that is less visible and does not require the use of other removal methods.
Reduced hair growth is desired in the axilla area (fossa axillaris), where deodorants and anti-perspirants are used to control odor trapped within the axillary hairs. It would be desired to have products for under-arm use, which combine deodorant or anti-perspirant activities with reduced hair growth activity.
African type hair is unique in its morphology—a kinky hair shaft with variations in diameter. This complex shaft structure creates the need for specialized grooming products and procedures to ensure that the African type hair maintains cosmetic desired properties.
It is desired to have products that reduce this complexity and make the African type hair more manageable, improving its appearance.
It would be desirable to provide a method for chemically or naturally affecting hair growth, hair follicle and hair shaft size and hair shaft pigmentation, which does not cause unwanted side effects to the user.
In accordance with the present invention, we have found compositions and methods for affecting changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation by topically applying to the skin of a mammal an effective amount of a topically active composition comprising protease inhibitors, botanical extracts, and in particular legume extracts including, but not limited to, soymilk, for a period of time sufficient to affect hair growth, hair follicle and hair shaft size and hair shaft pigmentation. Such topically active compositions may be further combined with other active ingredients including, but not limited to, synthetic or naturally occurring isoflavones, to enhance the desired effects on hair growth and pigmentation.
The compositions and methods of this invention provide a unique, convenient means for delaying hair growth, reducing hair follicle and hair shaft size and hair shaft pigmentation, by using serine protease inhibitors, botanical extracts of the legume family, and in particular, but not limited to, soymilk, containing serine protease inhibitory activity, and their combinations with isoflavones.
The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which:
As used herein, “mammal” shall mean any member “of the higher vertebrate animals comprising the class Mammalia,” as defined in Webster's Medical Desk Dictionary 407 (1986), and includes but is not limited to humans. As used herein “(%, w/v)” shall mean grams of a given component per 100 ml of the total composition.
Topically active agents suitable for use in the composition of the present invention include protease inhibitors and natural plant extracts having protease inhibitory activity and mixtures thereof. Preferred protease inhibitors are serine protease inhibitors, and in particular Soybean Trypsin Inhibitor (“STI”) and the soybean-derived Bowman Birk Inhibitor (“BBI”). Preferred botanical extracts are of the legume family and in particular bean extracts, such as soymilk. Preferably, the protease inhibitors are present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 20% (w/v), and more preferably from about 0.001% (w/v) to about 5% (w/v). Preferably, botanical aqueous extracts such as soymilk are present in an amount of 10-99% (v/v), and more preferably from 50-99% (v/v).
This invention also relates to compositions and methods for affecting changes in mammalian hair growth, hair pigmentation and hair shaft and follicle size, comprising topically applying to skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
We have unexpectedly found that when topically active agents such as described above, and in particular soymilk or soymilk containing formulations, are enriched with isoflavones, and in particular soybean-derived isoflavones, the inhibitory effect on hair growth, hair dimensions and hair pigmentation is enhanced.
Preferably, the isoflavones are present in the botanical aqueous extracts such as soymilk in an amount of 0.000005-15% (v/v), and more preferably from 0.00001-10% (v/v).
If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition of the present invention may be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the hair follicle and the skin.
The pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof. These will be combined in an amount which will not affect the serine protease inhibitory activity, in order to produce cosmetic or pharmaceutical products such as, non-exclusively, essences, creams, lotions, pastes, gels, powders, patches or injectables and the like for the reduction of hair growth, hair size and hair pigmentation.
The compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect. For example, the compositions of this invention may be applied in conjunction with one or more products whose purpose is to facilitate the removal of hair to actually remove hair, reduce hair visibility, improve hair style or improve hair management. The compositions of this invention may be applied topically prior to, during or following hair removal. They may be applied topically concurrently with one or more of the following group: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask or bath additives.
The compositions of this invention may be applied daily for at least four to eight weeks, by which an effect upon the appearance of hair should be observed. Application may be continued as long as desired to maintain the condition of the hair. Daily application to the face may mitigate the condition of pseudofolliculitis barbae and/or hirsutism; application to the axillary area may reduce hair growth under the arms and application to the scalp and hair may assist in managing and styling African-type hair.
The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect changes in mammalian hair growth, hair follicle and hair shaft size and hair shaft pigmentation. As used herein “amount effective” shall mean an amount sufficient to cover the region of skin surface where a delay in hair growth and hair pigmentation and reduced hair size are desired. Preferably, the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 μl /cm2 to about 500 μl /cm2 of topically active agent is present when a delay in hair growth, hair size and hair pigmentation is desired.
We have unexpectedly found that when topically active agents, such as soymilk, or isoflavone-enriched soymilk are topically applied to an animal's skin, a significant delay in hair growth, hair follicle and hair shaft size and hair shaft pigmentation was achieved. We further believe that since the hair growth cycle for humans is often slower than that for mice, it is further likely that the hair growth delay in humans would be considerably longer than in mice.
The invention illustratively disclosed herein suitably might be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof.
C57BI/6 or C3H mice (male and female) were obtained from Charles River (Kingston, NY), at 8-10 weeks of age and were in the resting (telogen) phase of their respective hair cycle. Hair growth was induced by wax depilation (plucking) of each respective animal's back fur according to the procedure set forth in Stenn, et al., “Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration,” 6 Skin Pharmacol., 125-134 (1993). In C57Bl/6 and C3H mice, 8-10 weeks old, the growth phase (anagen) starts synchronously in all hair follicles at the time of depilation. As illustrated in Table 1, the following observations were noticed at the induction site:
As shown in Table 1, the hair growth was visible several days after depilation as the pink skin of the animal began to darken. This is likely due to hair pigmentation in the shaft since the C57BI/6 and C3H mice contained melanocytes only in the hair follicles and not in the dorsal epidermis. Similar hair growth pattern was documented in our international application No. PCT/US 97/11033, when chemical depilation using commercially available products was performed.
Since the murine hair cycle varies not only between strains, but also amongst individual animals, the status of the hair cycle was analyzed in each animal on study. A 2 cm by 1 cm skin sample was isolated from each mouse with scissors, fixed with a 10% buffered formalin solution having a pH of about 6.9-7.1 at 25° C. (Stephens Scientific), and then formed into a paraffin block according to well-known procedures. The block was then microtomed, and sections were stained with H&E or Fontana-Mason stain. Sections were examined histologically in order to verify the phase of the hair cycle, the size of the hair follicle and hair shaft and the level of hair pigmentation, using procedures well known in the art. Hair length was assessed visually, and by using a low magnification (×8) dissecting microscope.
This Example, as well as the one described in our international application No. PCT/US 97/11033, shows that the hair growth cycle for C57BI/6 and C3H mice averaged about 25 days and reports similar timing of hair follicle and shaft development regardless of the method used for depilation.
One way to make soymilk is to soak the soybeans in deionized or purified water for several hours, and grind them after they were fully hydrated, with the addition of small quantities of water. (The grinding process allows the soybean milk to be extracted). After collection, the soybean milk may be filtered to remove any residual parts of the bean husk. The soymilk used in the formulations described below can be fresh soymilk as described above, or may be made from soybean powder and water. The soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze-dried and the resulting soymilk may or may not be filtered. Such prepared soymilk may have from about 1 to about 90% by weight dry soybean powder. Another example is the use of soymilk powder, made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization. Other methods of soybean extraction could also be used to create the active ingredients in the formulations described below. For example, the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the serine protease inhibitory activity of the soybean will be retained, and preferably that the protein STI will remain intact.
The soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. For example, but not limiting to, soybean strains particularly rich in its Soybean Trypsin Inhibitor (STI) content or in isoflavone content, or growth conditions that result in STI or isoflavone enrichment in the bean, might be preferred. It should be noted that the soy products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others. If necessary, the odor of the compositions of this invention may be reduced by using soybean products derived from specific strains of soybeans known to produce reduced-odor, including, but not limited to, lipoxygenase-2-deficient beans and those having modified sugar profile, and the like. A process to reduce oxygen levels in the formulation may also reduce the odor. Various masking agents or fragrances may also be used to mask the odor.
The compositions of this invention may further comprise surfactants, moisturizers, humectants, conditioners, fragrances, colorants, preservatives, anti-oxidants, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, foaming agents, cosmetic adjuvants, buffering agents or mixtures thereof.
The compositions of this invention may be left on the skin for a period sufficient to effect changes. For example, the compositions of this invention may be applied to the skin daily treatment for at least about four weeks, more preferably, the composition should applied daily for at least eight weeks.
Another method according to this invention is a method to reduce or prevent pseudofolliculitis barbae. Daily application of the compositions of this invention may reduce or prevent this condition. The compositions of this invention may also be applied daily to the axilliary area to reduce hair growth. Furthermore, the compositions of this invention may be applied daily to the scalp to style and improve management of African type hair.
As shown in our co-pending U.S. patent application Ser. No. 09/110,409, numerous soymilk-based formulations could be used to reduce pigmentation. All these formulations could also be used to reduce hair growth. Some particularly preferred examples of soymilk formulations and soymilk formulations containing isoflavones are shown in table 2 below. An example for an isoflavones preparation that could be used in this invention is Flavosterone SE from Ichimaru, Japan, which contains about 0.1% pure isoflavones. In all these formulations, soymilk could be replaced with the appropriate quantities of soybean powder or soymilk powder and water.
Soybean trypsin inhibitor (STI) and Bowman-Birk inhibitor (BBI), from Sigma-Aldrich Corporation were mixed into a 0.1M phosphate buffered saline (PBS, Gibco-BRL, Gaithersburg, MA), pH 7.4, in concentrations of 1% to 0.001% (w/v). Four volumes of the resulting solutions were then mixed with 1 volume of (100 mg/ml) liposomes vehicle, which was prepared by the methods described in Niemiec et. al, in order to yield the topically active composition. Non-ionic liposomes preparations, such as those disclosed in Niemiec et al., “Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model,” 12 Pharm. Res. 1184-88 (1995) (“Niemiec”), which is incorporated by reference herein in its entirety, are well known in the art, and are described our U.S. patent application Ser. No. 09/110,409. GDL liposomes were prepared as set forth in Niemiec, et al., above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M, pH 7.4 (Gibco-BRL of Gaithersburg, Md.) were used as the aqueous phase in the preparation of the liposomes.
C57Bl/6 mice were induced for a new hair cycle as described in Example 1, and treated daily with soymilk.
ANIMALS were observed daily for their hair growth pattern, and skin biopsies were taken at important time points of the hair cycle. As a result of soymilk treatment the hair growth of the treated mice was delayed, and their hairs were visibly thinner, and smoother to touch. Treated mice did not show skin darkness at days 7-8 of the hair cycle, as expected, and hair shafts were not visible at days 11-12 as in the control animals. In average, the hair cycle of the soymilk treated mice was delayed by 3-6 days.
Histological examination of the biopsied skin samples confirmed these observations. As shown in
In order to verify that the effect of soymilk on hair growth is not specific to C57Bl/6 mice, we repeated the experiment described in Example 4 using the brown haired (Agouti) C3H mice. The results of these experiments were similar both visually and histologically. Soymilk delayed hair growth and reduced hair follicle and hair shaft size and pigment deposition in the C3H mice.
Histological analysis confirmed these visual observations. As shown in the upper panel of
In search for a mechanism to explain the effect of soymilk on hair growth, we tested the effect of the soymilk-derived serine protease inhibitors, STI and BBI.
We had shown earlier that these proteins induce depigmentation in skin, by affecting the PAR-2 pathway (U.S. patent application Ser. No. 09/110,409).
The experiments described in Example 4 were repeated using STI, BBI, and soymilk. STI and BBI were used in a PBS-liposome vehicle as described in Example 3. Visual observations throughout the hair cycle confirmed that both STI and BBI could delay hair growth and reduce hair follicle and hair shaft size, similar to soymilk (see hair pictures in
Histological analysis confirmed these finding. As shown in
In order to support the hypothesis that STI and BBI in soymilk are involved in the hair growth effects described above, we tested soymilk for its serine protease inhibitory activity. An enzymatic assay was performed using “Enzchek”, a protease digestion fluorescent test system made by Molecular Probes of Eugene, Oreg. Using 100 units of trypsin (from Sigma chemicals, St. Louis Mo.) the test system produced fluorescence reading of about 1100 units. This reaction was inhibited with increasing concentrations of STI, as expected from a known trypsin inhibitor. Serial dilutions of soymilk were tested in this assay, and found to inhibit trypsin activity. As shown in
The histological analyses of soymilk treated skin samples described in the examples above show dramatic reduction in pigment deposition within the hair follicle. To further understand the mechanism of soymilk-induced depigmentation, we studied tyrosinase, the key enzyme in melanogenesis and Tyrosinase-Related Protein-1 (TRP-1), the enzyme that stabilizes tyrosinase. C57Bl/6 and C3H mice were treated as described above, and samples were collected throughout the study for protein analysis. Protein extraction and Western blot analysis were performed using standard procedures, such as the one described in Current Protocols in Cell Biology, Edited by Juan S. Bonifacino et al. Chapter 6: Electrophoresis and Immunoblotting. Copyright 1999 by John Wiley & Sons, Inc., which is incorporated herein by reference in its entirety. An example of one such study is shown in
Equal amounts of skin-extracted proteins were probed with the anti-tyrosinase antibody “anti PEP1”, and with the anti-TRP-1 antibody “anti PEP7” which are described in Jimenez, M., Kameyama, K., Maloy, W L, Tomita Y., and Hearing, V. Mammalian tyrosinase: biosynthesis, processing and modulation by melanocyte stimulating hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34, and Jimenez, M., K., Maloy, WL, and Hearing, V. Specific identification of an authentic tyrosinase clone. J. Biol. Chem. (1989) 264:3397-3403, which are incorporated herein by reference in their entirety.
As shown in
An individual male with dark facial hair who shaves daily was treating the right side of his face with soymilk, immediately after shaving, for five weeks. By the third week, and more noticeably by the forth week, the hair of the treated side was visually lighter and felt smoother to touch. Digital pictures at different magnifications were taken throughout the treatment period, using Hi-Scope. These pictures clearly demonstrate the reduced size and thickness of the hair shafts at the treated side. An example of such pictures is shown in
Hair was wax-depilated of two symmetrical areas of the medial part of the legs, below the knee, in one individual. One leg was treated daily, for four weeks, with soymilk. Visual observations indicate slower hair growth on the treated site. Hair shafts were reduced in number and were shorter and thinner than those of the untreated site, as shown in
The experiments described in Example 4 were repeated, using two formulations described in Table 2 above, Soymilk Essence 23 which is a soymilk-based formulation, and soymilk Essence 30 which is identical to Soymilk Essence 23 except the addition of 5% of a 0.1% isoflavones extract. As shown in
The experiments described in Example 4 were repeated, using formulations described in Table 2 above, of soymilk essence with or without increasing concentrations of isoflavones. These Soy Essence formulations were compare to similar formulations, where the soymilk component only was replaced with water.
These three sets of formulations (Soy Essence, isoflavones, Soy Essence containing additional isoflavones) were prepared to test the possibility that isoflavones might be sufficient for the effect observed on hair growth.
Soymilk Essence formulations containing 1, 5 and 10% of a 0.1% isoflavones containing extract result in a superior effect on hair growth. However, formulations containing isoflavones but no soymilk demonstrate milder, and not as superior effect as when combined with soymilk. This example demonstrates that soymilk formulations containing isoflavone could reduce hair growth. This example further demonstrates that soymilk formulations containing isoflavones reduce hair growth to a higher degree than formulations containing isoflavones alone.
The efficacy and irritancy potential of Soymilk Essence 23 and 30 compared to a placebo formulation were examined in a blinded placebo-controlled four-week test with twelve pre-menopausal female panelists ages 29 to by evaluations by the study investigator, self-assessment by panelists and Hi-scope image analysis. Panelists signed an Informed Consent and were instructed about study procedures and expectations and were asked to shave that night. At the baseline visit the following day, two test lotions were distributed to each panelist (Day 1), a placebo lotion and either soymilk Essence 23 or 30. The lotions were randomly assigned to either the right leg or left leg. The test lotions and placebo were used on the respective legs for the duration of the study with no other lotions used on the lower legs. Panelists were instructed to apply the test lotions twice daily, morning and evenings and were also instructed to try to refrain from shaving their lower legs until after each weekly evaluation. On evaluation days, the investigator visually inspected the panelists' legs for any clinical signs of irritation and compared legs for hair growth attenuation. Self-assessment questionnaires were completed by panelists at each evaluation time point (Weeks 1, 2, 3 and 4). In addition, Hi-scope images (2.5 cm in diameter for each image, KH-2400R, Hirox) were obtained at each time point using a MX-MACROZ lens (Hirox).
No panelists dropped from the study for any product-related reason. No signs of irritation were seen in any of the study panelists at any time point, nor was any irritation reported when self-assessed by panelists at any time point during the study.
For the purpose of hair counts all hair, including “stubble”, were counted in the given 2.5 cm field for each panelist at each time point. Results showed a decrease in lower leg hair counts by week 5 for Soymilk Essence 30 and by week 4 for Soymilk Essence 23. The placebo treated legs did not show a change in mean leg hair counts throughout the study although the standard deviations were large. The growth rate was calculated by dividing the length of time (in days) since the panelist last shaved, by the average length of leg hairs for that panelist, which was calculated from the hi-scope images using Image Pro Plus analysis for each panelist at each test site. The results are documented in Table 3, demonstrating that both Soymilk Essences 23 and 30 treatments resulted in reduced hair growth rate compared to placebo.
Results from panelists' self-assessment questionnaires showed that panelists felt that the test lotions attenuated hair growth and softened the feel of leg hair, compared to the placebo lotion. Panelists felt that the hair felt less coarse and less stubbley. The majority of the panelists believed that the test lotions were attenuating leg hair growth or altering the texture of the hair so that it felt smoother and less coarse. Hi Scope analysis further demonstrated that the hair re-growth following treatment with Soymilk Essence 23 or 30 seemed to be growing in the same direction and was more uniform in shape, texture and appearance. In contrast, the hair that re-grew on the placebo-treated legs grew in different directions, differing in length, angle of growth and thickness.
This Example clearly demonstrate the effect of soymilk formulations in delaying and reducing hair growth, and enabling the growth of softer, less coarse and more managed and directionally-organized hair.
This application claims the benefit of U.S. Provisional application 60/145,774, filed Jul. 27, 1999.
Number | Name | Date | Kind |
---|---|---|---|
2876164 | Wershaw | Mar 1959 | A |
2924525 | Kruse et al. | Feb 1960 | A |
3097947 | Kemmerer | Jul 1963 | A |
3625976 | Theimer | Dec 1971 | A |
3755560 | Dickert et al. | Aug 1973 | A |
4007266 | Choay | Feb 1977 | A |
4056637 | Hagiwara et al. | Nov 1977 | A |
4151304 | Evans | Apr 1979 | A |
4190671 | Vanstone et al. | Feb 1980 | A |
4219569 | Glenn | Aug 1980 | A |
4223018 | Belle | Sep 1980 | A |
4254105 | Fukuda | Mar 1981 | A |
4272544 | Cella et al. | Jun 1981 | A |
4278570 | Flom | Jul 1981 | A |
4279930 | Hall et al. | Jul 1981 | A |
4297348 | Frazier | Oct 1981 | A |
4331692 | Drevici et al. | May 1982 | A |
4333927 | Ofuchi et al. | Jun 1982 | A |
4368187 | Flom et al. | Jan 1983 | A |
4370315 | Greff et al. | Jan 1983 | A |
4382960 | Flom | May 1983 | A |
4386067 | Guillon | May 1983 | A |
4421769 | Dixon et al. | Dec 1983 | A |
4427670 | Ofuchi et al. | Jan 1984 | A |
4434095 | Chipens et al. | Feb 1984 | A |
4437895 | Koulbanis et al. | Mar 1984 | A |
4439418 | Möller et al. | Mar 1984 | A |
4462981 | Smith | Jul 1984 | A |
4477434 | Kosaka | Oct 1984 | A |
4486448 | Ser et al. | Dec 1984 | A |
4488564 | Grollier et al. | Dec 1984 | A |
4512973 | Dennis | Apr 1985 | A |
4515778 | Kastell | May 1985 | A |
4524067 | Arichi et al. | Jun 1985 | A |
4537782 | Millet et al. | Aug 1985 | A |
4550035 | Smith | Oct 1985 | A |
4578267 | Salamone | Mar 1986 | A |
4584190 | Tejima et al. | Apr 1986 | A |
4603146 | Kligman | Jul 1986 | A |
4604281 | Deckner et al. | Aug 1986 | A |
4612192 | Scheuffgen et al. | Sep 1986 | A |
4690821 | Smith et al. | Sep 1987 | A |
4707293 | Ferro | Nov 1987 | A |
4727088 | Scott et al. | Feb 1988 | A |
4760096 | Sakai et al. | Jul 1988 | A |
4793991 | Slimak | Dec 1988 | A |
4824662 | Hofmann | Apr 1989 | A |
4834076 | Millet et al. | May 1989 | A |
4847267 | Deckner et al. | Jul 1989 | A |
4851214 | Walters et al. | Jul 1989 | A |
4859458 | Salamone et al. | Aug 1989 | A |
4867964 | Forestier et al. | Sep 1989 | A |
4871530 | Grollier et al. | Oct 1989 | A |
4885169 | Gazzani | Dec 1989 | A |
4895839 | Bombardelli | Jan 1990 | A |
4906457 | Ryan | Mar 1990 | A |
4943462 | Komerska et al. | Jul 1990 | A |
4960588 | Hoshowski et al. | Oct 1990 | A |
4960764 | Figueroa, Jr. et al. | Oct 1990 | A |
4970216 | Deckner et al. | Nov 1990 | A |
4971825 | Kitazume et al. | Nov 1990 | A |
4978528 | Degre | Dec 1990 | A |
5002761 | Mueller et al. | Mar 1991 | A |
5006337 | Motitschke et al. | Apr 1991 | A |
5032382 | Grollier | Jul 1991 | A |
5032400 | Wiersum et al. | Jul 1991 | A |
5043323 | Bombardelli et al. | Aug 1991 | A |
5057417 | Hammonds et al. | Oct 1991 | A |
5077038 | Hofmann | Dec 1991 | A |
5077040 | Bergmann et al. | Dec 1991 | A |
5104655 | Bombardelli et al. | Apr 1992 | A |
5110603 | Rau | May 1992 | A |
5116605 | Alt | May 1992 | A |
5118671 | Bombardelli et al. | Jun 1992 | A |
5130142 | Wong et al. | Jul 1992 | A |
5147859 | Bombardelli et al. | Sep 1992 | A |
5166139 | Bombardelli et al. | Nov 1992 | A |
5171577 | Griat et al. | Dec 1992 | A |
5179091 | Lesieur et al. | Jan 1993 | A |
5188823 | Shapiro et al. | Feb 1993 | A |
5192332 | Lang et al. | Mar 1993 | A |
5194252 | Hofmann | Mar 1993 | A |
5217717 | Kennedy et al. | Jun 1993 | A |
5229104 | Sottery et al. | Jul 1993 | A |
5231090 | Hsia | Jul 1993 | A |
5248495 | Patterson et al. | Sep 1993 | A |
5254331 | Mausner | Oct 1993 | A |
5260065 | Mathur et al. | Nov 1993 | A |
5270042 | Whitham | Dec 1993 | A |
5276058 | Satoh et al. | Jan 1994 | A |
5304482 | Sambrook et al. | Apr 1994 | A |
5306444 | Kitamura et al. | Apr 1994 | A |
5310734 | Losch et al. | May 1994 | A |
5322839 | Voegeli | Jun 1994 | A |
5352443 | Kubo et al. | Oct 1994 | A |
5362494 | Zysman et al. | Nov 1994 | A |
5364886 | Löliger et al. | Nov 1994 | A |
5393519 | Dowell et al. | Feb 1995 | A |
5397497 | Jakobson et al. | Mar 1995 | A |
5407675 | Etemad-Moghadam | Apr 1995 | A |
5411742 | Sebag | May 1995 | A |
5427814 | Löliger | Jun 1995 | A |
5428026 | Colarow | Jun 1995 | A |
5438044 | Losch et al. | Aug 1995 | A |
5439672 | Zabotto et al. | Aug 1995 | A |
5443839 | Meybeck | Aug 1995 | A |
5443840 | Morancais et al. | Aug 1995 | A |
5444092 | Collins | Aug 1995 | A |
5446605 | Umehara | Aug 1995 | A |
5466452 | Whittle | Nov 1995 | A |
5468473 | Mullen | Nov 1995 | A |
5498420 | Mentrup Edgar et al. | Mar 1996 | A |
5503832 | De Stoutz | Apr 1996 | A |
5505946 | Kennedy et al. | Apr 1996 | A |
5510391 | Elson | Apr 1996 | A |
5523308 | Costanzo et al. | Jun 1996 | A |
5539129 | Zysman et al. | Jul 1996 | A |
5545399 | Lee et al. | Aug 1996 | A |
5547661 | Sun et al. | Aug 1996 | A |
5554647 | Perricone | Sep 1996 | A |
5565493 | Nakata et al. | Oct 1996 | A |
5567420 | McEleney et al. | Oct 1996 | A |
5569663 | Ribier et al. | Oct 1996 | A |
5571503 | Mausner | Nov 1996 | A |
5578297 | Mellul et al. | Nov 1996 | A |
5589181 | Bencsits | Dec 1996 | A |
5595984 | Blank | Jan 1997 | A |
5597814 | Blank | Jan 1997 | A |
5601833 | Ribier et al. | Feb 1997 | A |
5603949 | Meybeck et al. | Feb 1997 | A |
5605894 | Blank | Feb 1997 | A |
5607666 | Masson | Mar 1997 | A |
5607692 | Ribier et al. | Mar 1997 | A |
5614180 | Chung | Mar 1997 | A |
5614215 | Ribier et al. | Mar 1997 | A |
5616572 | Blank | Apr 1997 | A |
5618522 | Kaleta et al. | Apr 1997 | A |
5620692 | Potter et al. | Apr 1997 | A |
5622690 | Potter et al. | Apr 1997 | A |
5626868 | Morancais et al. | May 1997 | A |
5629015 | Ribier et al. | May 1997 | A |
5629301 | Blank | May 1997 | A |
5631318 | Ito et al. | May 1997 | A |
5635165 | Panitch | Jun 1997 | A |
5637316 | Ribier et al. | Jun 1997 | A |
5639785 | Kung | Jun 1997 | A |
5641509 | Gross et al. | Jun 1997 | A |
5643583 | Voultoury et al. | Jul 1997 | A |
5643587 | Scancarella et al. | Jul 1997 | A |
5643601 | Gross et al. | Jul 1997 | A |
5650166 | Ribier et al. | Jul 1997 | A |
5652230 | Blank | Jul 1997 | A |
5653988 | Gerber et al. | Aug 1997 | A |
5660853 | Hansenne-Richoux | Aug 1997 | A |
5665367 | Burger et al. | Sep 1997 | A |
5670547 | Milstein et al. | Sep 1997 | A |
5674511 | Kacher et al. | Oct 1997 | A |
5676935 | Mellul et al. | Oct 1997 | A |
5676956 | Duffy et al. | Oct 1997 | A |
5679374 | Fanchon et al. | Oct 1997 | A |
5681571 | Horngren et al. | Oct 1997 | A |
5681852 | Bissett | Oct 1997 | A |
5683380 | Eckhouse et al. | Nov 1997 | A |
5683683 | Scafidi | Nov 1997 | A |
5686102 | Gross et al. | Nov 1997 | A |
5688763 | Hammonds, Jr. et al. | Nov 1997 | A |
5691327 | Blank | Nov 1997 | A |
5712356 | Bothe et al. | Jan 1998 | A |
5720772 | Eckhouse | Feb 1998 | A |
5723148 | Love | Mar 1998 | A |
5741496 | Khaiat | Apr 1998 | A |
5753612 | Mitrani | May 1998 | A |
5755814 | Berg et al. | May 1998 | A |
5762916 | Ansmann et al. | Jun 1998 | A |
5766628 | Nürnberg et al. | Jun 1998 | A |
5776917 | Blank et al. | Jul 1998 | A |
5780456 | Blank | Jul 1998 | A |
5780457 | Blank | Jul 1998 | A |
5780458 | Blank | Jul 1998 | A |
5780459 | Blank et al. | Jul 1998 | A |
5786345 | Blank et al. | Jul 1998 | A |
5786346 | Blank | Jul 1998 | A |
5789396 | Blank et al. | Aug 1998 | A |
5795879 | Blank | Aug 1998 | A |
5801163 | Blank | Sep 1998 | A |
5804216 | Terren et al. | Sep 1998 | A |
5807545 | Coffindaffer et al. | Sep 1998 | A |
5824702 | Wei | Oct 1998 | A |
5833965 | Sun et al. | Nov 1998 | A |
5834013 | Ribier et al. | Nov 1998 | A |
5834513 | Ptchelintsev | Nov 1998 | A |
5840717 | Blank | Nov 1998 | A |
5843907 | Sakai et al. | Dec 1998 | A |
5843926 | Blank | Dec 1998 | A |
5863546 | Swinehart | Jan 1999 | A |
5869031 | Tarroux et al. | Feb 1999 | A |
5869470 | Blank et al. | Feb 1999 | A |
5871480 | Tankovich | Feb 1999 | A |
5871743 | Chajuss | Feb 1999 | A |
5871823 | Anders et al. | Feb 1999 | A |
5880314 | Shinomiya et al. | Mar 1999 | A |
5885593 | Epstein | Mar 1999 | A |
5885596 | Parab | Mar 1999 | A |
5885600 | Blum et al. | Mar 1999 | A |
5885617 | Jordan | Mar 1999 | A |
5885948 | Glenn, Jr. et al. | Mar 1999 | A |
5888522 | Pickart | Mar 1999 | A |
5908618 | Lorant | Jun 1999 | A |
5912175 | Wille, Jr. | Jun 1999 | A |
5916577 | Golz et al. | Jun 1999 | A |
5928654 | Duranton | Jul 1999 | A |
5928658 | Kishida et al. | Jul 1999 | A |
5928889 | Bakich et al. | Jul 1999 | A |
6750229 | Seiberg et al. | Jul 1999 | B2 |
5936052 | Bothe et al. | Aug 1999 | A |
5942479 | Frankenbach et al. | Aug 1999 | A |
5945095 | Mougin et al. | Aug 1999 | A |
5945109 | Schmidt et al. | Aug 1999 | A |
5952373 | Lanzendörfer et al. | Sep 1999 | A |
5958387 | Bara et al. | Sep 1999 | A |
5958946 | Styczynski et al. | Sep 1999 | A |
5961980 | Kennedy | Oct 1999 | A |
5962015 | Delrieu et al. | Oct 1999 | A |
5962441 | Blank | Oct 1999 | A |
5965153 | Allen | Oct 1999 | A |
5972355 | Knight et al. | Oct 1999 | A |
5981450 | Fabry et al. | Nov 1999 | A |
5985338 | Suh et al. | Nov 1999 | A |
5985809 | Frankenbach et al. | Nov 1999 | A |
5985842 | Miljkovic | Nov 1999 | A |
5990291 | Waggle et al. | Nov 1999 | A |
6004915 | Elliott et al. | Dec 1999 | A |
6013250 | Cannell et al. | Jan 2000 | A |
6013255 | Edens et al. | Jan 2000 | A |
6017549 | Knight et al. | Jan 2000 | A |
6017893 | Segelman | Jan 2000 | A |
6018001 | Hiratani et al. | Jan 2000 | A |
6019962 | Rabe et al. | Feb 2000 | A |
6030931 | Vinski et al. | Feb 2000 | A |
6033680 | Dixon et al. | Mar 2000 | A |
6045548 | Furumoto et al. | Apr 2000 | A |
6045779 | Mueller et al. | Apr 2000 | A |
6048520 | Hoshowski | Apr 2000 | A |
6051602 | Bissett | Apr 2000 | A |
6054137 | Breton et al. | Apr 2000 | A |
6060070 | Gorbach | May 2000 | A |
6063398 | Gueret | May 2000 | A |
6080393 | Liu et al. | Jun 2000 | A |
6093411 | Bissett | Jul 2000 | A |
6096327 | Lezdey et al. | Aug 2000 | A |
6126933 | Warne et al. | Oct 2000 | A |
6139899 | Matsuura et al. | Oct 2000 | A |
6180662 | Lanzendörfer et al. | Jan 2001 | B1 |
6183761 | Bissett et al. | Feb 2001 | B1 |
6183762 | Deckers et al. | Feb 2001 | B1 |
6555143 | Miller et al. | Feb 2001 | B2 |
6217572 | Tobinick | Apr 2001 | B1 |
6248350 | Mori et al. | Jun 2001 | B1 |
6261603 | McElwain | Jul 2001 | B1 |
6272883 | Bruder et al. | Aug 2001 | B2 |
6273885 | Koop et al. | Aug 2001 | B1 |
6323219 | Costanzo | Nov 2001 | B1 |
6358242 | Cecchetti | Mar 2002 | B1 |
6365802 | Kridl | Apr 2002 | B2 |
6399083 | Pillai et al. | Jun 2002 | B1 |
6413546 | He et al. | Jul 2002 | B1 |
6423747 | Lanzendörfer | Jul 2002 | B1 |
6433025 | Lorenz | Aug 2002 | B1 |
6447809 | Krumhar et al. | Sep 2002 | B1 |
6461348 | Bertan et al. | Oct 2002 | B1 |
6461627 | Ichioka | Oct 2002 | B1 |
6485484 | Connors et al. | Nov 2002 | B1 |
6544255 | Stewart | Apr 2003 | B2 |
6551606 | Golz-Berner et al. | Apr 2003 | B1 |
6558656 | Mann | May 2003 | B2 |
20020034489 | Wiegland | Mar 2002 | A1 |
20020035046 | Lukenbach | Mar 2002 | A1 |
20020065300 | Seiberg et al. | May 2002 | A1 |
20020160061 | Saliou et al. | Oct 2002 | A1 |
20020160062 | Liu et al. | Oct 2002 | A1 |
20020160063 | Miller et al. | Oct 2002 | A1 |
20020182166 | Martin | Dec 2002 | A1 |
20020192313 | Saliou et al. | Dec 2002 | A1 |
20020197244 | Seiberg et al. | Dec 2002 | A1 |
20030064049 | Seiberg et al. | Apr 2003 | A1 |
20030224075 | Liu et al. | Dec 2003 | A1 |
20040009142 | Zambaux et al. | Jan 2004 | A1 |
20040062731 | Seiberg et al. | Apr 2004 | A1 |
20040063593 | Wu et al. | Apr 2004 | A1 |
20040067244 | Friedman | Apr 2004 | A1 |
20050008665 | Batzer | Jan 2005 | A1 |
20050019279 | Goppel | Jan 2005 | A1 |
20050281776 | Courcoux | Dec 2005 | A1 |
20070009459 | Magnant | Jan 2007 | A1 |
20070041931 | Morelli | Feb 2007 | A1 |
20070160564 | Liu et al. | Jul 2007 | A1 |
Number | Date | Country |
---|---|---|
199870006 | May 1998 | AU |
1081899 | Feb 1994 | CN |
1 094 279 | Nov 1994 | CN |
1146876 | Apr 1997 | CN |
1166960 | Dec 1997 | CN |
4432947 | Mar 1996 | DE |
19634206 | Mar 1998 | DE |
19818849 | Oct 1998 | DE |
0421021 | Jun 1989 | EP |
0 341 745 | Nov 1989 | EP |
0 393 532 | Oct 1990 | EP |
0 476 311 | Mar 1992 | EP |
0473502 | Mar 1992 | EP |
0 508 886 | Oct 1992 | EP |
0 532 465 | Mar 1993 | EP |
0 574 352 | Dec 1993 | EP |
0 581 624 | Feb 1994 | EP |
0 581 624 | Feb 1994 | EP |
0 582 239 | Feb 1994 | EP |
0 582 239 | Feb 1994 | EP |
0 643 083 | Mar 1995 | EP |
0 643 960 | Mar 1995 | EP |
0 655 470 | May 1995 | EP |
0273202 | Jun 1995 | EP |
0 661 037 | Jul 1995 | EP |
0707851 | Apr 1996 | EP |
0707851 | Apr 1996 | EP |
0 713 106 | May 1996 | EP |
0 758 687 | Feb 1997 | EP |
0774249 | May 1997 | EP |
0 814 116 | Dec 1997 | EP |
0811595 | Dec 1997 | EP |
0 963 761 | Dec 1999 | EP |
1 074 240 | Feb 2001 | EP |
1077 063 | Feb 2001 | EP |
1 192 938 | Apr 2002 | EP |
1 210 946 | Jun 2002 | EP |
1 236 402 | Sep 2002 | EP |
1 236 465 | Sep 2002 | EP |
1 348 441 | Oct 2003 | EP |
1 647 278 | Apr 2006 | EP |
2 596 986 | Oct 1987 | FR |
2 641 696 | Jul 1990 | FR |
2 685 202 | Jun 1993 | FR |
2803747 | Jul 2001 | FR |
2 811 226 | Jan 2002 | FR |
1098951 | Jan 1968 | GB |
58-225003 | Jun 1982 | JP |
58225004 | Dec 1983 | JP |
59187756 | Oct 1984 | JP |
60061513 | Apr 1985 | JP |
63-68512 | Sep 1986 | JP |
6-2036304 | Feb 1987 | JP |
62 036304 | Feb 1987 | JP |
62036304 | Feb 1987 | JP |
63-316711 | Jun 1987 | JP |
196106 | Oct 1987 | JP |
63-96120 | Apr 1988 | JP |
63135310 | Jun 1988 | JP |
63-227515 | Sep 1988 | JP |
1093519 | Apr 1989 | JP |
1096106 | Apr 1989 | JP |
3-127713 | Oct 1989 | JP |
02-286165 | Nov 1990 | JP |
5-320061 | May 1991 | JP |
5-25027 | Jul 1991 | JP |
5-320024 | May 1992 | JP |
4-169514 | Jun 1992 | JP |
04283518 | Oct 1992 | JP |
5015574 | Jan 1993 | JP |
5-25027 | Feb 1993 | JP |
05025027 | Feb 1993 | JP |
5114905 | May 1993 | JP |
5-213729 | Aug 1993 | JP |
5-246932 | Sep 1993 | JP |
899891 | Jan 1994 | JP |
6145061 | May 1994 | JP |
7304655 | May 1994 | JP |
812560 | Jun 1994 | JP |
8-020597 | Jul 1994 | JP |
6192085 | Jul 1994 | JP |
06256156 | Sep 1994 | JP |
6256156 | Sep 1994 | JP |
7010772 | Jan 1995 | JP |
925212 | Jul 1995 | JP |
925214 | Jul 1995 | JP |
7196527 | Aug 1995 | JP |
7196529 | Aug 1995 | JP |
7304655 | Nov 1995 | JP |
08012531 | Jan 1996 | JP |
8012560 | Jan 1996 | JP |
8040824 | Feb 1996 | JP |
8059450 | Mar 1996 | JP |
08081336 | Mar 1996 | JP |
8143442 | Jun 1996 | JP |
408143442 | Jun 1996 | JP |
8333260 | Dec 1996 | JP |
09 025212 | Jan 1997 | JP |
9025212 | Jan 1997 | JP |
9025213 | Jan 1997 | JP |
9025214 | Jan 1997 | JP |
090 59166 | Mar 1997 | JP |
90 59166 | Mar 1997 | JP |
9077638 | Mar 1997 | JP |
9176033 | Jul 1997 | JP |
10-046196 | Feb 1998 | JP |
10-139654 | May 1998 | JP |
10120542 | May 1998 | JP |
10120542 | May 1998 | JP |
10139639 | May 1998 | JP |
10139654 | May 1998 | JP |
10-175815 | Jun 1998 | JP |
410226642 | Aug 1998 | JP |
11322548 | Nov 1999 | JP |
11346695 | Dec 1999 | JP |
200191459 | Jul 2000 | JP |
2000-351720 | Dec 2000 | JP |
2000 302678 | Oct 2001 | JP |
2001-271096 | Oct 2001 | JP |
2004-000019 | Jan 2004 | JP |
92-8851 | Oct 1992 | KR |
92-8853 | Oct 1992 | KR |
2066992 | Sep 1996 | RU |
WO 8707838 | Dec 1987 | WO |
WO 9104283 | Apr 1991 | WO |
WO 9107166 | May 1991 | WO |
WO 9209639 | Jun 1992 | WO |
WO 9209650 | Jun 1992 | WO |
WO 9406485 | Mar 1994 | WO |
WO 9407462 | Apr 1994 | WO |
WO 9504609 | Feb 1995 | WO |
WO 9509002 | Apr 1995 | WO |
WO 9509011 | Apr 1995 | WO |
WO 9524885 | Sep 1995 | WO |
WO 9609806 | Apr 1996 | WO |
WO 9619483 | Jun 1996 | WO |
WO 9619491 | Jun 1996 | WO |
WO 9624371 | Aug 1996 | WO |
WO 9624392 | Aug 1996 | WO |
WO 9629050 | Sep 1996 | WO |
WO 9630035 | Oct 1996 | WO |
WO 9630396 | Oct 1996 | WO |
WO 9631194 | Oct 1996 | WO |
WO 9637497 | Nov 1996 | WO |
WO 9640121 | Dec 1996 | WO |
WO 9640199 | Dec 1996 | WO |
WO 9711033 | Mar 1997 | WO |
WO 9718904 | May 1997 | WO |
WO 9735998 | Oct 1997 | WO |
WO 9739733 | Oct 1997 | WO |
WO 9801107 | Jan 1998 | WO |
WO 9802134 | Jan 1998 | WO |
WO 9802138 | Jan 1998 | WO |
WO 9805333 | Feb 1998 | WO |
WO 9808503 | Mar 1998 | WO |
WO 9809987 | Mar 1998 | WO |
WO 9817246 | Apr 1998 | WO |
WO 9833089 | Jul 1998 | WO |
WO 9849153 | Nov 1998 | WO |
WO 9900110 | Jan 1999 | WO |
WO 9904752 | Feb 1999 | WO |
WO 9909065 | Feb 1999 | WO |
WO 9915917 | Apr 1999 | WO |
WO 9924003 | May 1999 | WO |
WO 9930729 | Jun 1999 | WO |
WO 9936050 | Jul 1999 | WO |
WO 9939682 | Aug 1999 | WO |
WO 9957178 | Nov 1999 | WO |
WO 0015188 | Mar 2000 | WO |
WO 0043049 | Jul 2000 | WO |
WO 0051554 | Sep 2000 | WO |
WO 0051554 | Sep 2000 | WO |
WO 0062740 | Oct 2000 | WO |
WO 0062740 | Oct 2000 | WO |
WO 0062741 | Oct 2000 | WO |
WO 0062741 | Oct 2000 | WO |
WO 0062743 | Oct 2000 | WO |
WO 0062743 | Oct 2000 | WO |
WO 0062744 | Oct 2000 | WO |
WO 0062745 | Oct 2000 | WO |
WO 00162744 | Oct 2000 | WO |
WO 0069404 | Nov 2000 | WO |
WO 0069406 | Nov 2000 | WO |
WO 0069407 | Nov 2000 | WO |
WO 0069408 | Nov 2000 | WO |
WO 0074699 | Dec 2000 | WO |
WO 0076458 | Dec 2000 | WO |
WO 0129163 | Apr 2001 | WO |
WO 0134099 | May 2001 | WO |
WO 0134909 | May 2001 | WO |
WO 0135920 | May 2001 | WO |
WO 02 07697 | Jan 2002 | WO |
WO 0207697 | Jan 2002 | WO |
WO 02064104 | Aug 2002 | WO |
WO 02067988 | Sep 2002 | WO |
WO 02074280 | Sep 2002 | WO |
WO 03032941 | Apr 2003 | WO |
WO 03039502 | May 2003 | WO |
WO 2004022024 | Mar 2004 | WO |
WO 2005097216 | Oct 2005 | WO |
Number | Date | Country | |
---|---|---|---|
60145774 | Jul 1999 | US |